Abstract
COVID-19 vaccine hesitancy among adolescents poses a challenge to the global effort to control the pandemic. This multi-country survey aimed to assess the levels and determinants of COVID-19 vaccine hesitancy among adolescents in sub-Saharan Africa between July and December 2021. The survey was conducted using computer-assisted telephone interviewing among adolescents in five sub-Saharan African countries, Burkina Faso, Ethiopia, Ghana, Nigeria, and Tanzania. A rural area and an urban area were included in each country (except Ghana, which only had a rural area), with approximately 300 adolescents in each area and 2803 in total. Sociodemographic characteristics and perceptions and attitudes on COVID-19 vaccines were measured. Vaccine hesitancy was defined as definitely not getting vaccinated or being undecided on whether to get vaccinated if a COVID-19 vaccine were available. Log-binomial models were used to calculate the adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for associations between potential determinants and COVID-19 vaccine hesitancy. The percentage of COVID-19 vaccine hesitancy was 15% in rural Kersa, 24% in rural Ibadan, 31% in rural Nouna, 33% in urban Ouagadougou, 37% in urban Addis Ababa, 48% in rural Kintampo, 64% in urban Lagos, 76% in urban Dar es Salaam, and 88% in rural Dodoma. Perceived low necessity, concerns about vaccine safety, and concerns about vaccine effectiveness were the leading reasons for hesitancy. Healthcare workers, parents or family members, and schoolteachers had the greatest impacts on vaccine willingness. Perceived lack of safety (aPR: 3.61; 95% CI: 3.10, 4.22) and lack of effectiveness (aPR: 3.59; 95% CI: 3.09, 4.18) were associated with greater vaccine hesitancy. The levels of COVID-19 vaccine hesitancy among adolescents are alarmingly high across the five sub-Saharan African countries, especially in Tanzania. COVID-19 vaccination campaigns among sub-Saharan African adolescents should address their concerns and misconceptions about vaccine safety and effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
Funding Statement
This work was supported by institutional support from Harvard T.H. Chan School of Public Health, Boston, MA Harvard University Center for African Studies, Boston, MA Heidelberg Institute of Global Health, Germany, and the George Washington University Milken Institute School of Public Health, Washington, DC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board at Harvard T.H. Chan School of Public Health and ethical review boards in each country and area, including the Nouna Health Research Center Ethical Committee and National Ethics Committee in Burkina Faso, the Institutional Ethical Review Board of Addis Continental Institute of Public Health in Ethiopia, Kintampo Health Research Centre Institutional Ethics Committee in Ghana, the University of Ibadan Research Ethics Committee and National Health Research Ethics Committee in Nigeria, and the University of Dodoma, Muhimbili University of Health and Allied Sciences, and National Institute for Medical Research in Tanzania.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Individual participant data cannot be shared because of the requirements for ethical approvals and data transfer agreements in this multi-country study. The de-identified dataset supporting this research may be made available following a submitted request to ghp{at}hsph.harvard.edu and the completion of ethical approval and data transfer agreement from the ethical review authority in each country and site. The complete adolescent instrument used for the Round 2 survey is available on the website of the Harvard University Center for African Studies (https://africa.harvard.edu/files/african-studies/files/arise_covid-19_survey_round_2_adolescent_household_survey_questionnaire.pdf).
